Cancer As a Risk Factor for Cardiovascular Disease

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2017 Apr 20

PMID 28421481

Citations 34

Authors

Dana Elena Giza

Gloria Iliescu

Saamir Hassan

Konstantinos Marmagkiolis

Cezar Iliescu

Affiliations

Soon will be listed here.

Abstract

Improvements in early diagnosis and cancer treatments have contributed to high survival rates for many cancer patients. However, these patients often die of cardiovascular disease rather than recurrence of their cancer. Heart disease manifesting after cancer may be due to several mechanisms: shared cardiovascular risks between cancer and cardiovascular disease, inflammatory states associated with malignancies, and/or cardiotoxic effects of cancer therapy. Cancer treatment increases the risk of cardiovascular diseases directly by damaging critical structures of the heart or indirectly by promoting accelerated atherosclerosis. Estimating cardiovascular risk by using advanced imaging and monitoring of the cardiac biomarkers can be used for early detection and treatment of subclinical cardiac injury. Better knowledge of these early and late cardiac effects in cancer patients will enable adoption of both primary and secondary prevention measures of long-term treatment complications in cancer survivors.

Citing Articles

Common biological processes and mutual crosstalk mechanisms between cardiovascular disease and cancer.

Gao H, Chen Z, Yao Y, He Y, Hu X Front Oncol. 2024; 14:1453090.

PMID: 39634266 PMC: 11614734. DOI: 10.3389/fonc.2024.1453090.

Transcatheter aortic valve replacement before to breast cancer management: case report and literature review.

Aquino-Bruno H, Muratalla-Gonzalez R, Garcia-Garcia J, Morales-Portano J, Melendez-Ramirez G, Ahu-Chandomi Y Eur Heart J Case Rep. 2024; 8(9):ytae475.

PMID: 39290523 PMC: 11407282. DOI: 10.1093/ehjcr/ytae475.

Outcomes of patients with active cancer after transcatheter aortic valve replacement: an updated meta-analysis.

Felix N, Nogueira A, Carvalho P, Costa T, Tramujas L, Generoso G Cardiooncology. 2024; 10(1):55.

PMID: 39252142 PMC: 11386488. DOI: 10.1186/s40959-024-00256-8.

Mechanisms of Myocardial Ischemia in Cancer Patients: A State-of-the-Art Review of Obstructive Versus Non-Obstructive Causes.

Balanescu D, Bloomingdale R, Donisan T, Yang E, Parwani P, Iliescu C Rev Cardiovasc Med. 2024; 23(7):227.

PMID: 39076910 PMC: 11266791. DOI: 10.31083/j.rcm2307227.

Association of lifestyle modification with the development of cardiovascular disease in gastric cancer patients who underwent gastrectomy: A nationwide population-based study.

Kim B, Han K, Cho S Cancer Med. 2024; 13(14):e70038.

PMID: 39046111 PMC: 11267560. DOI: 10.1002/cam4.70038.

References

Carrozza Jr J, Kuntz R, LeVine M, Pomerantz R, Fishman R, Mansour M . Angiographic and clinical outcome of intracoronary stenting: immediate and long-term results from a large single-center experience. J Am Coll Cardiol. 1992; 20(2):328-37. DOI: 10.1016/0735-1097(92)90098-8. View

Nuver J, Smit A, Wolffenbuttel B, Sluiter W, Hoekstra H, Sleijfer D . The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol. 2005; 23(16):3718-25. DOI: 10.1200/JCO.2005.02.176. View

Grunwald M, Howie L, Diaz Jr L . Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature. J Clin Oncol. 2011; 30(2):e11-4. DOI: 10.1200/JCO.2011.38.5278. View

Lim S, Wilson S, Hunter A, Hill J, Beale P . Takotsubo cardiomyopathy and 5-Fluorouracil: getting to the heart of the matter. Case Rep Oncol Med. 2013; 2013:206765. PMC: 3866884. DOI: 10.1155/2013/206765. View

Smith S, Auseon A . Chemotherapy-induced takotsubo cardiomyopathy. Heart Fail Clin. 2013; 9(2):233-42, x. DOI: 10.1016/j.hfc.2012.12.009. View

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T . Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4):220-41. DOI: 10.3322/caac.21149. View

Suter T, Ewer M . Cancer drugs and the heart: importance and management. Eur Heart J. 2012; 34(15):1102-11. DOI: 10.1093/eurheartj/ehs181. View

Mueller C, Roskamm H, Neumann F, Hunziker P, Marsch S, Perruchoud A . A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J Am Coll Cardiol. 2003; 41(6):969-73. DOI: 10.1016/s0735-1097(02)02974-1. View

Fuster V, Moreno P, Fayad Z, Corti R, Badimon J . Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005; 46(6):937-54. DOI: 10.1016/j.jacc.2005.03.074. View

10.

Tefferi A, Letendre L . Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011; 86(7):610-1. DOI: 10.1002/ajh.22051. View

11.

Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G . Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995; 91(6):1676-88. DOI: 10.1161/01.cir.91.6.1676. View

12.

Burgdorf C, Nef H, Haghi D, Kurowski V, Radke P . Tako-tsubo (stress-induced) cardiomyopathy and cancer. Ann Intern Med. 2010; 152(12):830-1. DOI: 10.7326/0003-4819-152-12-201006150-00026. View

13.

van Nimwegen F, Schaapveld M, Janus C, Krol A, Petersen E, Raemaekers J . Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015; 175(6):1007-17. DOI: 10.1001/jamainternmed.2015.1180. View

14.

Khakoo A, Yeh E . Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol. 2008; 5(11):655-67. DOI: 10.1038/ncponc1225. View

15.

Ranpura V, Hapani S, Chuang J, Wu S . Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010; 49(3):287-97. DOI: 10.3109/02841860903524396. View

16.

Krone R . Managing coronary artery disease in the cancer patient. Prog Cardiovasc Dis. 2010; 53(2):149-56. DOI: 10.1016/j.pcad.2010.06.004. View

17.

Sawaya H, Sebag I, Plana J, Januzzi J, Ky B, Cohen V . Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011; 107(9):1375-80. PMC: 3703314. DOI: 10.1016/j.amjcard.2011.01.006. View

18.

Lipshultz S, Miller T, Scully R, Lipsitz S, Rifai N, Silverman L . Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012; 30(10):1042-9. PMC: 3341148. DOI: 10.1200/JCO.2010.30.3404. View

19.

Hancock S, Tucker M, Hoppe R . Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993; 270(16):1949-55. View

20.

Darby S, Cutter D, Boerma M, Constine L, Fajardo L, Kodama K . Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010; 76(3):656-65. PMC: 3910096. DOI: 10.1016/j.ijrobp.2009.09.064. View